Literature DB >> 18830743

Acute increase in hepatic arterial flow during TIPS identified by intravascular flow measurements.

Boris Radeleff1, Christof-Matthias Sommer, Tobias Heye, Ruben Lopez-Benitez, Peter Sauer, Jan Schmidt, Haus-Ulrich Kauczor, Goetz Martin Richter.   

Abstract

The purpose of this study was to investigate alterations of hepatic arterial flow during transjugular intrahepatic portosystemic stent shunt (TIPS) applying intravascular Doppler sonography. This prospective monocenter study included 25 patients with liver cirrhosis (alcohol induced [n = 19], chronic hepatitis associated [n = 3], primary biliary cirrhosis associated [n = 1], and cryptogenic [n = 2]) successfully treated with TIPS. All patients underwent intravascular hepatic arterial flow measurements during TIPS using an endoluminal flow sensor. The average arterial peak velocity (APV) and the maximum arterial peak velocity (MPV) were registered. Twenty-two patients (88%) showed increased APV, one patient (4%) showed unaffected APV, and two patients (8%) showed decreased APV after TIPS. The average portosystemic pressure gradient decreased significantly, from 22.0 +/- 5.1 mmHg before TIPS to 11.0 +/- 4.1 mmHg after TIPS (-50.0%; p < 0.0001). The average APV increased significantly, from 41.9 +/- 17.8 cm/s before TIPS to 60.7 +/- 19.0 cm/s after TIPS (+44.9%; p < 0.0001). The average MPV increased significantly, from 90.8 +/- 31.7 cm/s before TIPS to 112.6 +/- 34.9 cm/s after TIPS (+24.0%; p = 0.0002). These changes in perfusion set in within seconds after TIPS tract formation in all the patients with increased APV. We conclude that TIPS-induced portosystemic decompression leads to a significant increase in hepatic arterial flow. The changes occurred within seconds, suggesting a reflex-like mechanism.

Entities:  

Mesh:

Year:  2008        PMID: 18830743     DOI: 10.1007/s00270-008-9435-0

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  5 in total

1.  Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.

Authors:  Zhu Wang; Hailong Zhang; He Zhao; Xiaoze Wang; Jiaywei Tsauo; Xuefeng Luo; Xiao Li
Journal:  Diagn Interv Radiol       Date:  2014-11       Impact factor: 2.630

2.  Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification.

Authors:  Paolo Fonio; Andrea Discalzi; Marco Calandri; Andrea Doriguzzi Breatta; Laura Bergamasco; Silvia Martini; Antonio Ottobrelli; Dorico Righi; Giovanni Gandini
Journal:  Radiol Med       Date:  2017-05-16       Impact factor: 3.469

3.  Occult Hepatocellular Carcinoma Associated With Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant Recipients.

Authors:  Lauren N Krumeich; Jenna Mancinelli; Andy Cucchiara; Kevin Eddinger; David Aufhauser; Drew W Goldberg; Evan S Siegelman; Mark Rosen; K Rajender Reddy; Maarouf Hoteit; Emma E Furth; Kim M Olthoff; Abraham Shaked; Matthew Levine; Peter Abt
Journal:  Liver Transpl       Date:  2021-07-21       Impact factor: 6.112

4.  Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension.

Authors:  Pei-Jing Cui; Jing Yao; Yin Zhu; Zheng-Yun Zhang; Jun Yang
Journal:  Gastroenterol Res Pract       Date:  2017-08-10       Impact factor: 2.260

5.  Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS).

Authors:  Johannes Chang; Alexia Dumitrache; Nina Böhling; Jasmin Abu-Omar; Carsten Meyer; Deike Strobel; Julian Luetkens; Andreas Minh Luu; Jürgen Rockstroh; Christian P Strassburg; Jonel Trebicka; Maria A Gonzalez-Carmona; Milka Marinova; Michael Praktiknjo
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.